Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors

Post time 2024-4-18 17:09:12

journal：Clinical Cancer Research

Authors：Neeltje Steeghs; Carlos Gomez-Roca; Kristoffer S. Rohrberg; Morten Mau-Sorensen; Debbie Robbrecht; Josep Tabernero; Samreen Ahmed; Maria E. Rodriguez-Ruiz; Caroline Ardeshir; Daniela Schmid; Nassim Sleiman; Carl Watson; Hanna Piper-Lepoutre; David Dejardin; Stefan Evers; Christophe Boetsch; Jehad Charo; Volker Teichgraber; Ignacio Melero

Published date：--

DOI：10.1158/1078-0432.ccr-23-3567

PDF link：https://aacrjournals.org/clincan ... 987/ccr-23-3567.pdf

Article link：http://dx.doi.org/10.1158/1078-0432.ccr-23-3567

Article Source：American Association for Cancer Research (AACR)。

Remark：

Post time 2024-4-18 17:09:13

: This post has been completed
Completed attachments will be deleted within 24 hours.

[AACR] Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[AACR] Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors Copy